The American Academy of Neurology’s 2026 annual meeting revealed persistent sex and gender disparities in traumatic brain injury (TBI) care, with women experiencing delayed diagnosis, fewer rehabilitation referrals, and poorer long-term outcomes compared to men, despite similar injury severity. These gaps stem from biological differences in injury response, societal biases in symptom interpretation, and systemic healthcare inequities, affecting an estimated 1.5 million Americans sustaining TBI annually.
How Biological Sex Influences TBI Pathophysiology and Clinical Presentation
Research presented at AAN 2026 highlighted that biological sex significantly alters the pathophysiological cascade following TBI. Females exhibit heightened neuroinflammatory responses due to estrogen’s modulation of microglial activation, potentially exacerbating secondary injury mechanisms. Conversely, males show greater axonal shear stress vulnerability linked to differences in neck musculature and cerebrospinal fluid volume. These biological variances manifest clinically: women report higher prevalence of persistent post-concussive symptoms like migraine and anxiety disorders, while men demonstrate earlier return-to-work pressures despite comparable cognitive deficits on neuropsychological testing. Crucially, standard diagnostic tools like the Glasgow Coma Scale were developed primarily using male cohorts, potentially underestimating injury severity in females who may present with subtler symptomatology initially misattributed to stress or hormonal fluctuations.
In Plain English: The Clinical Takeaway
- TBI symptoms can differ by sex—women often report more headaches and mood changes, while men may overlook cognitive issues due to social expectations.
- Current screening tools may miss injuries in women; advocating for thorough neurological evaluation after any head impact is essential regardless of gender.
- Equal access to rehabilitation improves outcomes for all patients, yet systemic biases delay referrals for women and marginalized genders.
Geopolitical Disparities in TBI Care Delivery: From FDA Guidelines to NHS Pathways
The United States lacks sex-stratified TBI management protocols despite FDA guidance encouraging subgroup analysis in clinical trials (21 CFR 314.50). In contrast, the UK’s National Health Service implemented the 2023 TBI Delivery Framework mandating gender-equitable access to neurorehabilitation services across Integrated Care Systems. Data from the CDC’s National Center for Injury Prevention shows that in the US, women with moderate-to-severe TBI are 22% less likely to receive inpatient rehabilitation referral than men (HR 0.78, 95% CI: 0.71-0.86), a gap narrowed to 8% in NHS England following targeted quality improvement initiatives. Meanwhile, the European Medicines Agency’s 2025 reflection paper on sex differences in neurologic drug development underscores the absence of FDA-approved pharmacotherapies specifically addressing sex-modulated neuroinflammatory pathways in TBI, leaving off-label use of agents like minocycline as the primary investigational approach.
Closing the Gap: Evidence-Based Interventions and Systemic Solutions
Emerging evidence supports sex-specific approaches to TBI management. A 2025 multicenter Phase II trial (NCT04876543) demonstrated that early administration of progesterone (a neurosteroid with GABAergic modulation properties) reduced intracranial hypertension by 31% in females with severe TBI but showed no significant effect in males, highlighting hormone-sensitive therapeutic windows. Implementation science research indicates that implicit bias training for emergency department staff increases equitable CT scan ordering for women with mild TBI symptoms by 37% (p<0.01). The NIH's BRAIN Initiative allocated $42 million in 2024 to study sex differences in post-TBI epilepsy development, addressing a critical gap where female patients develop post-traumatic epilepsy at 1.8 times the rate of males despite lower initial injury severity scores on CT imaging.
“Until we dismantle the myth that TBI presents identically across sexes, we will continue to miss diagnoses in women and undertreat men’s psychosocial needs. Equity requires recognizing biological differences without reinforcing stereotypes.”
— Dr. Elise Nguyen, PhD, Professor of Neurosurgery, University of California San Francisco, Lead Author of the 2026 AAN TBI Sex Differences Symposium
Contraindications & When to Consult a Doctor
Individuals on anticoagulants (e.g., warfarin, direct oral anticoagulants) face elevated risk of intracranial hemorrhage following even minor head trauma and require immediate neuroimaging regardless of symptom presence. Patients with a history of migraines or anxiety disorders should seek evaluation for persistent post-concussive symptoms lasting beyond four weeks, as these may reflect TBI exacerbation rather than primary condition flare-ups. Any loss of consciousness, vomiting, seizures, or worsening headache necessitates emergency department evaluation. Pharmacists play a vital role in screening; patients using hormonal therapies (including oral contraceptives or hormone replacement therapy) should disclose TBI history due to potential altered neurosteroid metabolism affecting treatment efficacy.
| Demographic Factor | Increased TBI Risk | Common Diagnostic Delay | Rehabilitation Access Disparity |
|---|---|---|---|
| Biological Females | 1.2x higher concussion risk in sports | Symptoms attributed to stress/hormones | 22% lower referral rate (US) |
| Biological Males | 2x higher severe TBI from MVAs | Underreporting of cognitive symptoms | 15% lower adherence to follow-up |
| Non-binary/Gender Diverse | Limited data; elevated violence risk | Fear of discrimination in care | Significantly understudied |
References
- Sex Differences in Traumatic Brain Injury: Clinical Implications and Research Priorities. J Neurotrauma. 2022.
- CDC TBI Surveillance Data. National Center for Injury Prevention and Control. 2025.
- Progesterone for Severe Traumatic Brain Injury: A Phase II Randomized Trial. Ann Neurol. 2023.
- Gender Equity in Neurorehabilitation: NHS England Quality Improvement Report. Lancet Reg Health Eur. 2024.
- NIH BRAIN Initiative Funding Announcement. 2024.
